Innovate for health csem 17.09.2014xxx

1IBM Technology Day 2013, Keynote B. Dubuis11.6.2013

Click to edit Master title style

© BD, ROI© 2013 IBM Corporation

Biotech, Medtech and Bioconvergence

Dr. Benoit Dubuis, President BioAlps & Inartis-Network, Executive Director Campus Biotech

17.09.2014

HEALTH CARE “Medical revolution and new technologies”

The challenges

Towards bioconvergence

Our contribution

Anticipate the Future

HEALTH CARE “Medical revolution and new technologies”

The challenges

Towards bioconvergence

Our contribution


Crossing Visions14.04.23 | 4

MAJOR CHALLENGESIN HEALTHCARE

Therapeutic challenges

Demographics

Cost

Access

Variation in clinical practice

Inefficient use of information

Fragmented care versus integrated care

Duplication, defensive medicine & waste

Protracted adoption of innovation


CAUSESOF DEATH


DEMOGRAPHICS:WE LIVELONGER

Life

Exp

ecta

ncy

at B

irth

Benchmark: Life expectancy in imperial Rome was ~ 30 years

1900 1950 2010 2050

CH: 80.5

CH: 84.7

Age 60 – 2 BillionAge 80 – 380 MillionAge 100 – 2 Million

Benchmark: Life expectancy in imperial Rome was ~ 30 years

Age 60 – 2 BillionAge 80 – 380 MillionAge 100 – 2 Million


HEALTH CARECOSTS

3


THE BURDEN OFCHRONIC DISEASES

Healthcare spending for people with chronic conditions

Nearly half of us will havechronic conditions by 2030:

DiabetesNeurodegenerative DiseaseObesityHypertensionArthritisAtherosclerosisStrokeCancerDegenerative Joint diseaseDegenerative Spine DiseaseObstructive Lung Disease

Healthcare spending for people without chronic conditions

Chronic conditionsaccount for 83% of health care spending4

NEW NEEDS INNEURO-ENGINEERING

5

http://www.google.ch/url?sa=i&source=images&cd=&cad=rja&docid=Vd5_KMNxHxT3kM&tbnid=V6i9KHiJcTHiOM:&ved=0CAgQjRwwAA&url=http://www.medicalook.com/human_anatomy/systems/Sensory_organs.html&ei=ZJxyUtraHJCg7AbUzIC4AQ&psig=AFQjCNFpJZe2W0fyvuVu4aW13j5h7IXYvw&ust=1383329252537664

http://www.google.ch/url?sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&docid=sLjbr1pi_KTM0M&tbnid=gUnbHMpJlugH9M:&ved=0CAUQjRw&url=http://www.marsdd.com/news-insights/mars-reports/neurotechnology-focus-on-aging/&ei=vqByUuGqMMLX0QXX9IDoDw&bvm=bv.55819444,d.ZGU&psig=AFQjCNG-XIcsmG4HYLKAukWoY1mXWkvIyA&ust=1383330357883369

http://www.google.ch/url?sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&docid=oeS1cXthCJxmaM&tbnid=RwZQAywifzFFFM:&ved=0CAUQjRw&url=http://www.dibs.duke.edu/research/research-themes/neurotechnology&ei=LKFyUsqnEqOe0QXE0YDACw&bvm=bv.55819444,d.ZGU&psig=AFQjCNG-XIcsmG4HYLKAukWoY1mXWkvIyA&ust=1383330357883369


TOWARDHEALTHIER

LIFEPast model

Present model

Compressed morbidity model

Healthy life

Healthy life

DiseaseDisability

DiseaseDisability

Healthy life Life years gainedDiseaseDisability



MEDTECH “Medical revolution and new technologies”

The challenges

Towards Bioconvergence

Our contribution



CHANGING FOCUSON HEALTH CARE

Technology convergence

Pharmacogenomics

3P medicine

Translational medicine

Wireless Health

TOWARDS ANINTEGRATED HEALTH SYSTEM

Rx 2009


INNOVATION BYBIOCONVERGENCE


EXPLORE INTERFACES


NEXT GENERATIONPLATFORM TECHNOLOGIES

NEWPRODUCTS

NEWSOLUTIONS


THE STRENGTHOF THE

NETWORKCLINICAL CENTERS

ACADEMIC CENTERS

COREFACILITIES

INDUSTRY START-UPS

191/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis

Interdisciplinarity (science driven)

What is a Stent

A small, mesh-like device made of metal

Acts as a support or scaffold, in keeping the vessel open

Stent helps to improve blood flow to the heart muscle and reduce

the pain of angina

80% of patients who have balloon angioplasty will have a stent

placed as well.

History

Percutaneous transluminal coronary angioplasty (PTCA) by

Gruntzig in 1977

Puel and Sigwart, in 1986, deployed the first coronary stent to act

as a scaffold

In 2001, drug-eluting stents (DES) were introduced as a strategy

to minimize restenosis

Types

Bare metal stents: Traditional method

May have an increased rate of

re-narrowing due to growth of scar

tissue in the stent, a condition called

Restenosis.

Drug-eluting stents:

Combat Restenosis

Coated with medications that are slowly released

to block the body's ability to form scar tissue

around the stent. The medication is delivered

directly to the site of the artery blockage.




The challenges

Towards an integrated health system

Our contribution

Innovation: The New Currency of

Competition


MICRO / NANO CLUSTER

BIOCLUSTER

A UNIQUE HUBFOR MEDTECH & BIOTECH

WORLD-CLASSACADEMIC

INSTITUTIONS

Generate KnowledgeCreate Opportunities

http://www.google.ch/url?sa=i&rct=j&q=unine+webmail&source=images&cd=&cad=rja&docid=ls4hqxEqQYjmxM&tbnid=Ycx3wi5j7TDUXM:&ved=0CAUQjRw&url=http://webmail.unine.ch/&ei=c7kcUtCSL87QsgbxwYCADw&bvm=bv.51156542,d.bGE&psig=AFQjCNFYFlln6Vih3MMBBMrS07mED5Blpg&ust=1377700590426161

http://www.google.ch/url?sa=i&rct=j&q=imt+neuchatel&source=images&cd=&cad=rja&docid=6V7tyk1fcFw4lM&tbnid=Jfkm5shguNRyqM:&ved=0CAUQjRw&url=http://actu.epfl.ch/news/epfl-boosts-presence-in-neuchatel/&ei=A7ocUuy_G8bCtQbig4GYBA&bvm=bv.51156542,d.bGE&psig=AFQjCNEomHBd4QltWUNRg8EgFO_179_32g&ust=1377700730221868

http://www.google.ch/url?sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&docid=KrEeDXidPkFzYM&tbnid=PwwGSRTFxAvoiM:&ved=0CAUQjRw&url=http://thomasputallaz.blog.tdg.ch/archive/2013/05/30/merck-serono-epfl-unige.html&ei=z8tBUoC5CcfGtQaxvoCABw&bvm=bv.52434380,d.bGE&psig=AFQjCNHIRIrIUym1U_AtezTN7wkYey5E8g&ust=1380130102861534


'evolutionary developmental biology'

Electronic health record'

Access to tools and knowledge


The shift to patient-empowering, information-leveraging technologies

“PI” (patient-empowering and information-leveraging) technologies


Molecular and personalized medicine

Proficient use of Information (e.health)

Genomic & physiology

Access, Cost and Quality of care


INNOVATIONThe New Currency of Competition


EXPLORE NEW AVENUES


WHEREHISTORY WRITES

TowardsCampus Biotech


WHEREHISTORY WRITESENSURING THAT

HISTORY GOES ON


NEWPATHS



ACCELERATETECH TRANSFER


SupportTechnology Transfer


INARTIS NETWORK, NTN

R&D Projects(CTI)

R&D Projects(CTI)

Workshops

EventsWorkshops

Events

NetworkingNetworking




The challenges

Towards an integrated health system

Our contribution



750 companties25’000 employees


Support the growthAnticipate the Future

Vitesse moyenne de croissance annuelle 95-00, 00-06Source: BAK, Basel Economics


A Successfull biocluster

EstablishedaccesstoCapital

ExperiencedBusiness and

LawFirms

Carve-Outs/Spinouts

ExperiencedEntrepreneur Innovation

Initiatives

World-ClassResearch

Institutions

ExperiencedTechnicalPeople

World-ClassBusinessSchools

PhD’s

MBA’s

Early-StageCompany

Late-StageEmerging/Public

PublicIndustryLeader

IP

CreateValuearound IP

CreateValue

C://DUBUIS, 2009

© 2014 INARTIS

© 2013 IBM Corporation

Find the slides on:

www.republic-of-innovation.ch

Dr. Benoit [email protected]

Health & Medicine

Innovate for health csem 17.09.2014xxx